Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
